Myclausen (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Myclausen, is an antimetabolite immunosuppressant presented as a tablet for oral use. It suppresses immune activity to prevent organ transplant rejection and to treat lupus nephritis and other autoimmune disorders.

GNH USA supplies Myclausen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable delivery to clinical sites across multiple regions.

Mycophenolate Mofetil is used to modulate immune responses in several transplant‑related and autoimmune conditions. - Organ transplant rejection prevention: Reduces the risk of acute and chronic rejection after kidney, heart or liver transplantation. - Lupus nephritis treatment: Helps control renal inflammation and preserve kidney function in patients with systemic lupus erythematosus. - Other autoimmune disorders: Provides immunosuppression for conditions such as vasculitis or dermatomyositis where T‑ and B‑cell activity contributes to disease.

Mycophenolate Mofetil may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: Gastrointestinal discomfort that may affect appetite. - Diarrhea: Loose stools that can lead to dehydration if severe. - Headache: Mild to moderate pain often alleviated with standard analgesics. - Upper respiratory infections: Increased susceptibility to common colds and sinusitis.

Serious or Rare Side Effects: - Bone marrow suppression: Leukopenia, anemia, or thrombocytopenia requiring monitoring. - Severe infections: Opportunistic infections such as Pneumocystis jirovecii pneumonia. - Hepatic toxicity: Elevated liver enzymes or hepatitis in rare cases.

When prescribing Mycophenolate Mofetil, clinicians should consider several safety measures. - Monitor blood counts: Perform regular complete blood count to detect leukopenia or anemia. - Assess renal function: Adjust therapy in patients with impaired kidney function. - Avoid in pregnancy: Contraindicated due to teratogenic risk (Category X). - Vaccination: Administer necessary vaccines before initiating therapy; live vaccines are contraindicated during treatment. - Drug interactions: Review concomitant medications for potential interactions. - Store at ambient temperature: Keep below 25 °C in original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Live vaccines: Increased risk of infection; avoid during treatment. - Other antimetabolites (e.g., azathioprine): Additive bone marrow suppression. - Strong CYP3A4 inducers (rifampin, carbamazepine): May markedly reduce drug exposure.

Moderate Interactions (Monitor Closely): - Antacids containing magnesium or aluminum: May reduce absorption; separate dosing by at least 2 hours. - Warfarin: May enhance anticoagulant effect; monitor INR closely. - ACE inhibitors or ARBs: May increase risk of hyperkalemia when combined with renal impairment.